Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $97.00

Merck & Co., Inc. (NYSE:MRKGet Rating) had its price target upped by equities research analysts at Barclays from $94.00 to $97.00 in a research note issued to investors on Tuesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 12.62% from the company’s current price.

A number of other research firms have also weighed in on MRK. JPMorgan Chase & Co. cut their target price on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a research note on Friday, January 28th. Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Mizuho began coverage on shares of Merck & Co., Inc. in a research note on Friday, April 1st. They set a “buy” rating and a $100.00 target price on the stock. Finally, SVB Leerink lowered their price target on Merck & Co., Inc. from $101.00 to $100.00 and set an “outperform” rating for the company in a report on Wednesday, April 6th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Buy” and an average price target of $90.88.

Shares of NYSE:MRK opened at $86.13 on Tuesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.27 and a quick ratio of 1.02. The firm has a market capitalization of $217.72 billion, a PE ratio of 16.76, a price-to-earnings-growth ratio of 1.42 and a beta of 0.45. The firm’s 50-day moving average is $79.31 and its two-hundred day moving average is $79.49. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $91.40.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its earnings results on Thursday, February 3rd. The company reported $1.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.46 by $0.34. Merck & Co., Inc. had a net margin of 26.02% and a return on equity of 47.24%. The firm had revenue of $13.25 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period in the prior year, the firm earned $1.32 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 7.19 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Financial Avengers Inc. raised its stake in shares of Merck & Co., Inc. by 115.8% during the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock worth $25,000 after purchasing an additional 176 shares during the last quarter. Front Row Advisors LLC raised its stake in shares of Merck & Co., Inc. by 89.4% during the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares during the last quarter. Moisand Fitzgerald Tamayo LLC raised its stake in shares of Merck & Co., Inc. by 78.0% during the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock worth $27,000 after purchasing an additional 156 shares during the last quarter. Okabena Investment Services Inc. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $27,000. Finally, Western Pacific Wealth Management LP purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $29,000. 72.05% of the stock is owned by institutional investors and hedge funds.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

The Fly logo

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.